Mark Norris

Investigator, CHEO Research Institute

Dr. Norris is involved in medical research exploring treatment and behavioural outcomes in youth with complex feeding and eating disorders. In addition to studies examining
adjunctive use of medication for EDs, he has investigated epidemiological rates of EDs in Canada, treatment studies that have utilized varying intensities and innovative measures to study outcomes in EDs, and investigations that examine medical complications of EDs. In addition to this area of study, Dr. Norris also collaborates with other Canadian investigators on studies that involve vulnerable adolescent populations.

Research Projects

  1. Cocreating research priorities for anorexia nervosa: The Canadian Eating Disorder Priority Setting Partnership


    This project, which closely followed the James Lind Alliance guidelines, solicited research priorities from the Canadian eating disorder community by means of a five‐step process including use of a survey, response collation, literature checking, interim ranking survey, and in‐person prioritization workshop.

  2. Characteristics and clinical trajectories of patients meeting criteria for avoidant/restrictive food intake disorder that are subsequently reclassified as anorexia nervosa


    Prospective longitudinal research that utilizes ARFID‐specific as well as traditional eating disorder diagnostic measures is required to better understand how patients with restrictive eating disorders that deny fear of weight gain can be differentiated and best treated.

  3. Severe alcohol intoxication among Canadian Youth: A 2-year surveillance study


    Although rates of alcohol use in adolescents have been steadily decreasing, results from this surveillance study suggest that severe intoxication arising from the use of alcohol alone, and with concurrent substance use, results in significant immediate health consequences in young adolescents.

  4. Development of the Ottawa Disordered Eating Screen for Youth: The ODES-Y


    Our findings suggest that the index test has utility as a short and accurate screening tool for earlier detection of disordered eating thoughts and behaviors in youth.

  5. Use of cyproheptadine to stimulate appetite and body weight gain: A systematic review


    CY appears to be a safe, generally well-tolerated medication that has utility in helping facilitate weight gain in patients drawn from a variety of underweight populations. Future prospective randomized controlled studies in low weight patients that include objective measures of appetite and intake are needed to better understand the mechanism by which CY augments weight gain.